Rate Video

EHA 2015 | Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia

Giuseppe Saglio • 12 Jun 2015

EHA 2015

Chronic Myeloid Leukemia Dasatinib Nilotinib

At the 20th Congress of the European Hematology Association (EHA), Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the role of second-generation tyrosine kinase inhibitors (TKIs), nilotinib and dasatinib, in the management of patients with chronic myeloid leukemia (CML).

Pros and cons of CML first-line therapy

Giuseppe Saglio • 18 Apr 2016

TKI-related toxicities in CML & the importance of long-term monitoring

Giuseppe Saglio • 28 Sep 2022

Update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia

Giuseppe Saglio • 12 Jun 2015

Benefits of second generation TKIs for CML in the frontline

Giuseppe Saglio • 12 Sep 2018

Related Videos

Involving patients in clinical trial design: a message to academia and industry

Generic vs. branded imatinib for CP-CML: a multicenter, observational study

Giuseppe Saglio

Pregnancy outcomes in CML patients

Ekaterina Chelysheva

CML-IT-MOS: clinical characteristics of CML patients not included in clinical trials

Giuseppe Saglio